Pfizer will work with researchers from University College London in the UK to try to develop stem cell-based therapies for …
AstraZeneca's Iressa is set to make a comeback after a European committee recommended its use for a sub-group of lung …
As a young child, I am reliably informed that "why" was my favourite word for an extended period. While that …
Biogen Idec has won approval for a new high-titre manufacturing process for its multiple sclerosis product Tysabri (natalizumab) which should …
GSK and Pfizer have agreed to merge their respective HIV businesses, creating a single specialist entity with total pro-forma sales …
The FDA has approved Novartis's Afinitor for advanced renal cell carcinoma patients who have progressed after first-line Sutent or Nexavar …
GlaxoSmithKline has announced a price freeze on its drugs and vaccines in Germany for 2009. The freeze applies to drugs …
Kuvan, the first treatment for two rare neurological disorders, has been launched in the UK, France and Germany.Merck Serono’s drug …
The UK government budget delivered in the gloom of the recession has provided good news for the industry, according to …
France's Sanofi-Aventis is planning a major capital investment programme in Beijing in a bid to bolster its position in the …
NICE has approved Bayer's anti-clotting treatment Xarelto, bringing it into line with Boehringer Ingelheim's rival Pradaxa. Xarelto (rivaroxaban) was assessed …
An underlying principle for joint working between the NHS and the pharmaceutical industry is that it brings benefits to patients. …
GSK has launched Alli, making it the first clinically proven over-the-counter weight loss aid to be available in pharmacies across …
An accord signed by economic ministers of the Association of Southeast Asian Nations, aimed at bringing manufacturing standards into line, …
Any positive effect on the pharmaceutical industry derived from the G20 summit and European Union summit will be indirect and …
AstraZeneca will not follow this year's emerging pharma trend towards mega-mergers and may instead look to smaller-scale deals, according to …